Last A$67.68 AUD
Change Today +0.15 / 0.22%
Volume 958.9K
CSL On Other Exchanges
As of 2:11 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

csl ltd (CSL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - A$72.82
52 Week Low
06/19/13 - A$56.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CSL LTD (CSL)

Related News

No related news articles were found.

csl ltd (CSL) Related Businessweek News

No Related Businessweek News Found

csl ltd (CSL) Details

CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Switzerland, Germany, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment manufactures, markets, and develops plasma therapies, including plasma products and recombinants that are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders, cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborn. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products, including biological products for human use; vaccines to prevent viral and bacterial diseases; prescription pharmaceuticals to treat a range of human medical conditions; in vitro diagnostic products; and antivenoms to treat victims of venomous snake and spider bites. The CSL Intellectual Property segment engages in the commercialization of intellectual property. In addition, the company markets various vaccines and antivenoms, as well as a range of pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

11,285 Employees
Last Reported Date: 08/13/13
Founded in 1916

csl ltd (CSL) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $1.9M
Chief Financial Officer
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Chief Scientific officer and Director of R&D
Total Annual Compensation: $1.2M
Executive Vice President of Commercial Operat...
Total Annual Compensation: $992.5K
Compensation as of Fiscal Year 2013.

csl ltd (CSL) Key Developments

CSL Ltd. Reports Earnings Results for the First Half Ended December 31, 2013

CSL Ltd. reported earnings results for the first half ended December 31, 2013. For the period, the company’s revenue was up $2,701.7 million against $2,583.7 million a year ago. EBIT was up $818 million, 5% or 2% at constant currency. NPAT at $646 million, up 3% and 2% in constant currency. Earnings per share, $1.33, up 7%, 5% at constant currency. Cash flow from operations at $513 million. EBITDA was $828.7 million against $799.8 million a year ago. Pre-tax profit was $802.4 million against $775.4 million a year ago. Return on equity was 19.6% against 17.8% a year ago.

CSL Ltd. Proposes Interim Dividend Payable on April 4, 2014

CSL Ltd. announced that since the end of the half-year the directors have recommended the payment of an interim dividend of 53.00 US cents against 50.00 US cents in 2012 per fully paid ordinary share, unfranked. The aggregate amount of the proposed interim dividend expected to be paid on 4 April 2014 out of retained earnings at 31 December 2013, but not recognised as a liability at the end of the half-year, is $256.6 million.

CSL Ltd., H1 2014 Earnings Call, Feb 12, 2014

CSL Ltd., H1 2014 Earnings Call, Feb 12, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSL:AU A$67.68 AUD +0.15

CSL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,139 JPY -1.00
Biocon Ltd 454.75 INR -2.45
Biogen Idec Inc $290.54 USD -0.94
Grifols SA €36.78 EUR +0.375
Shire PLC 2,925 GBp +25.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CSL Industry Range
Price/Earnings 25.1x
Price/Sales 6.1x
Price/Book 9.3x
Price/Cash Flow 24.6x
TEV/Sales 5.5x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at